Can I Take Lion's Mane with Vyleesi (Bremelanotide)?

What Vyleesi (Bremelanotide) Actually Does in the Body

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] It acts primarily at MC1R, MC3R, and MC4R receptors in the central nervous system, modulating dopaminergic and serotonergic pathways that govern sexual desire.

Pharmacokinetic Profile

After a 1.75 mg subcutaneous dose, bremelanotide reaches peak plasma concentration (Cmax) in roughly 1 hour and has a half-life of approximately 2.7 hours. [1] The drug is metabolized by hydrolysis of the amide bonds rather than hepatic CYP450 enzymes, which is important: it means the typical herb-drug interactions driven by CYP3A4 or CYP2C9 competition do not apply here. Lion's mane does not appear to meaningfully inhibit or induce the hydrolytic enzymes that clear bremelanotide.

Hemodynamic Effects to Know

The Vyleesi prescribing information documents transient blood pressure increases averaging 6 mmHg systolic and 3 mmHg diastolic, peaking at approximately 4 hours post-dose and resolving within 12 hours. [1] In the key RECONNECT trials (two Phase 3 studies, N=1,267 combined), nausea occurred in 40% of participants and flushing in 20%, both driven by peripheral melanocortin receptor activation. [2] These hemodynamic effects are the primary reason any vasoactive supplement warrants a second look before combining it with Vyleesi.

What Lion's Mane Does, and Why It Matters Here

Lion's mane is an edible fungus whose bioactive compounds fall into two classes: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both classes stimulate nerve growth factor (NGF) synthesis and secretion in vitro. [3]

Neurological Mechanism

A 2009 randomized, double-blind trial (N=30) by Mori and colleagues published in Phytotherapy Research showed that 3 g/day of dried Hericium erinaceus significantly improved Hasegawa Dementia Scale scores at 8, 12, and 16 weeks compared with placebo (P<0.001). [4] NGF upregulation is thought to underlie this benefit. The relevance to Vyleesi: both compounds influence central neurochemistry, though through entirely different receptor classes (melanocortin vs. Neurotrophin signaling). Direct receptor-level crosstalk has not been demonstrated in any published human study.

Platelet and Hemostatic Effects

This is the more clinically relevant concern. Hericium erinaceus extract inhibited ADP-induced platelet aggregation in vitro in a 2010 study, with an IC50 in the range seen with weak antiplatelet herbs. [5] A separate preclinical study found that polysaccharide fractions from lion's mane reduced thrombus formation in a murine model. [6] These are not human clinical data, but they establish a biological plausibility for additive bleeding risk if lion's mane is combined with other agents that stress hemostasis.

Bremelanotide itself is not an antiplatelet agent. The concern is indirect: because Vyleesi causes transient vasodilation and blood pressure fluctuation, adding even a mild platelet inhibitor to the mix could theoretically amplify bruising at the injection site or alter systemic hemostatic balance in women already taking aspirin, NSAIDs, or prescription anticoagulants. [1]

Immune Modulation

Lion's mane beta-glucans stimulate macrophage activation and natural killer cell activity. [7] Bremelanotide, as a melanocortin agonist, has documented anti-inflammatory effects via MC3R and MC4R in animal models. [8] Whether these opposing or complementary immune signals interact meaningfully at therapeutic doses used by women taking Vyleesi has not been studied.

Is This a Pharmacokinetic or Pharmacodynamic Interaction?

The short answer: pharmacodynamic, not pharmacokinetic.

CYP450 Pathway Analysis

Bremelanotide bypasses hepatic CYP450 metabolism almost entirely. The FDA label confirms the drug is primarily eliminated via peptide bond hydrolysis and renal excretion. [1] Lion's mane extracts show modest inhibition of CYP1A2 in some in vitro assays, but CYP1A2 does not govern bremelanotide clearance. [9] There is no pharmacokinetic basis for lion's mane to alter bremelanotide blood levels, prolong its half-life, or increase its systemic exposure.

Where the Pharmacodynamic Overlap Lives

The overlap is in three areas, all theoretical at current evidence levels:

1. Platelet function. Lion's mane inhibits aggregation; bremelanotide causes injection-site reactions that could be worsened by impaired local hemostasis.
2. Blood pressure. Vyleesi raises blood pressure transiently. Some rodent data suggest lion's mane polysaccharides may have modest hypotensive effects at high doses. [10] If both effects occurred simultaneously in the same direction, they could partially cancel out, or, if lion's mane has inconsistent directional effects in humans, the interaction could amplify the Vyleesi-driven pressor response.
3. Central neurochemical tone. Both agents act on pathways that influence arousal and mood, though no study has shown that lion's mane potentiates or blunts bremelanotide's effect on sexual desire scores.

The Three-Zone Safety Framework for This Combination

Because no head-to-head interaction trial exists, a risk-stratification approach is more useful than a flat "safe/unsafe" binary.

Zone 1: Lower-Risk Profile

A premenopausal woman with normal blood pressure, no bleeding history, and no concurrent anticoagulant or antiplatelet therapy. She takes lion's mane 500 to 1,000 mg of fruiting-body extract daily for cognitive support. For her, the combination is likely low-risk. Separating her lion's mane dose from her Vyleesi injection by at least 4 to 6 hours reduces the window of any pharmacodynamic overlap. She should monitor for unusual injection-site bruising and report any prolonged flushing (lasting beyond 12 hours) to her prescriber. [1]

Zone 2: Moderate-Risk Profile

A woman with borderline-high blood pressure (systolic 130 to 139 mmHg), or someone taking a daily low-dose aspirin (81 mg) for cardiovascular prevention. The additive platelet-inhibition signal from lion's mane, even if modest, sits on top of an already-stressed hemostatic baseline. The American Heart Association defines Stage 1 hypertension as 130 to 139/80 to 89 mmHg. [11] In this group, prescriber disclosure is not optional. A shared decision-making conversation about whether to pause lion's mane on Vyleesi-use days is reasonable.

Zone 3: Higher-Risk Profile

Any woman on warfarin, direct oral anticoagulants (apixaban, rivaroxaban), or prescription antiplatelets (clopidogrel, ticagrelor). She should not combine lion's mane with Vyleesi without explicit hematology or cardiology sign-off. The preclinical platelet data [5], combined with the hemodynamic stress of bremelanotide, creates a stacking-risk scenario that outpaces the available safety evidence.

What the Clinical Trial Record Says About Vyleesi Safety

The RECONNECT program enrolled 1,267 premenopausal women with generalized acquired HSDD across two Phase 3 randomized controlled trials. [2] The primary endpoint, the Female Sexual Function Index desire domain score, improved by a mean of 1.2 points on bremelanotide vs. 0.7 points on placebo (P<0.001). [2] Adverse events driving discontinuation were predominantly nausea (40%), flushing (20%), and injection-site reactions (11%). No serious cardiovascular events were attributed to the drug in these trials, but women with uncontrolled hypertension were excluded from enrollment. [1]

The FDA label carries a specific contraindication for women with cardiovascular disease or uncontrolled hypertension. [1] That contraindication does not mention supplements, but the physiological rationale extends to any agent that independently stresses blood pressure or hemostasis.

A 2023 real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) identified 312 reports mentioning bremelanotide, with nausea (28%), flushing (17%), and hyperpigmentation (9%) as the most common signals. [12] No reports specifically named lion's mane as a concomitant supplement, which reflects the broader problem of supplement underreporting in FAERS, not evidence of safety.

What the Evidence Says About Lion's Mane Safety

Hericium erinaceus has a favorable safety record in human trials. A 2010 clinical trial (N=30) using 3 g/day for 16 weeks reported no serious adverse events and normal liver and kidney function panels throughout. [4] A 2020 randomized trial (N=41) testing 1.8 g/day of H. Erinaceus in adults with mild cognitive impairment confirmed tolerability at 8 weeks with no hematologic abnormalities detected. [13]

Allergy Risk

Rare but documented: anaphylaxis to Hericium erinaceus has been reported. [14] Women who are sensitive to fungi or mushrooms should discuss this with their provider before starting lion's mane regardless of any concurrent medication.

Drug Interactions Flagged in Other Contexts

Beyond the platelet concern, lion's mane has shown mild inhibition of CYP2B6 in one in vitro study. [9] CYP2B6 metabolizes bupropion and cyclophosphamide, not bremelanotide. That interaction is therefore not relevant to this specific combination but matters if a woman is also on bupropion for mood or smoking cessation.

Dosing and Timing Recommendations

No formal dose-separation guideline exists specifically for this pairing. The following recommendations draw on the pharmacokinetic parameters of each agent:

• Bremelanotide's plasma concentration peaks at approximately 1 hour post-injection and returns to near-baseline by 12 hours. [1]
• Lion's mane polysaccharides reach peak plasma levels in roughly 2 to 4 hours after an oral dose based on pharmacokinetic modeling of similar beta-glucan compounds. [15]

Taking lion's mane in the morning and using Vyleesi in the early evening (or vice versa) creates a natural 8 to 10 hour separation for most dosing schedules. On days when Vyleesi is not used, lion's mane can be taken at any time without concern.

Women who take lion's mane daily (rather than on an as-needed basis) should inform their Vyleesi prescriber at the time of prescription. The Endocrine Society's 2023 position on supplement disclosure states that providers should proactively ask about all non-prescription products at every visit. [16] That bidirectional disclosure conversation is the single most practical safety step available given the current evidence gap.

Monitoring and Red Flags

After any Vyleesi injection, a woman taking lion's mane concurrently should watch for:

• Blood pressure elevation lasting beyond 12 hours (normal Vyleesi effect resolves by 12 hours). [1]
• Injection-site bruising larger than a 2-cm diameter circle.
• Flushing that persists or worsens after 4 hours post-injection.
• Any nausea accompanied by dizziness or near-fainting, which could signal a hemodynamic interaction.

The FDA advises women to check blood pressure before each Vyleesi dose and to not inject if resting systolic blood pressure exceeds 160 mmHg or diastolic exceeds 95 mmHg. [1] That threshold applies whether or not a supplement is in play.

Talking to Your Prescriber

The gap in direct interaction data is real and not a reason to panic. Bremelanotide's non-CYP metabolism makes it pharmacokinetically cleaner than most oral drugs, and lion's mane's antiplatelet effect is weak compared with prescription agents. A transparent conversation with your prescriber should cover:

• Your current lion's mane dose (mg per day, product standardization, fruiting body vs. Mycelium vs. Blend).
• Whether you take any other antiplatelet or anticoagulant medications.
• Your baseline blood pressure history.
• Any history of bleeding disorders or clotting conditions.

The North American Menopause Society recommends that all women using pharmacological HSDD therapies receive a full medication reconciliation, including herbals and dietary supplements, before and during treatment. [17] That standard applies directly here.